Testing Ripretinib against Sunitinib in GIST

Area of Science:

• Oncology
• Pharmacology

Background:

• The INTRIGUE trial investigated ripretinib versus sunitinib as second-line treatment for advanced gastrointestinal stromal tumors (GIST).
• Evaluating progression-free survival (PFS) and safety was the primary objective.

Discussion:

• Ripretinib did not meet the primary endpoint of non-inferiority to sunitinib for PFS in second-line GIST.
• A notable finding was the improved safety profile of ripretinib, with significantly fewer high-grade toxicities.

Key Insights:

• Second-line ripretinib is not superior to sunitinib in improving progression-free survival for advanced GIST.
• Ripretinib exhibits a superior safety and tolerability profile compared to sunitinib, with reduced severe adverse events like hypertension.

Outlook:

• Further research may explore ripretinib in different treatment lines or combinations for GIST.
• The improved safety profile could position ripretinib as a valuable option for specific patient populations or in combination therapies.